ENTRY       D09874                      Drug
NAME        Benralizumab (USAN/INN);
            Benralizumab (genetical recombination) (JAN);
            Fasenra (TN)
PRODUCT     FASENRA (AstraZeneca Pharmaceuticals LP)
FORMULA     C6492H10060N1724O2028S42
EXACT_MASS  145964.5332
MOL_WEIGHT  146054.4048
SEQUENCE    (Heavy chain)
            EVQLVQSGAE VKKPGASVKV SCKASGYTFT SYVIHWVRQR PGQGLAWMGY INPYNDGTKY
            NERFKGKVTI TSDRSTSTVY MELSSLRSED TAVYLCGREG IRYYGLLGDY WGQGTLVTVS
            SASTKGPSVF PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS
            SGLYSLSSVV TVPSSSLGTQ TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG
            GPSVFLFPPK  PKDTLMISRT  PEVTCVVVDV  SHEDPEVKFN  WYVDGVEVHN  AKTKPREEQY
            300 NSTYRVVSVL  TVLHQDWLNG  KEYKCKVSNK  ALPAPIEKTI  SKAKGQPREP
            QVYTLPPSRD  ELTKNQVSLT  CLVKGFYPSD  IAVEWESNGQ  PENNYKTTPP
            VLDSDGSFFL  YSKLTVDKSR  WQQGNVFSCS  VMHEALHNHY  TQKSLSLSPG  K
            (Light chain)
            DIQMTQSPSS LSASVGDRVT ITCGTSEDII NYLNWYQQKP GKAPKLLIYH TSRLQSGVPS
            RFSGSGSGTD FTLTISSLQP EDFATYYCQQ GYTLPYTFGQ GTKVEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H96, H148-H204, H265-H325, H371-H429, H230-H'230, H233-H'233, L23-L88, L134-L194, H224-L214)
  TYPE      Peptide
CLASS       Immunological agent
             DG02019  Interleukin inhibitor
REMARK      Therapeutic category: 2290
            ATC code: R03DX10
            Product: D09874<JP/US>
EFFICACY    Antiasthmatic, Anti-IL-5 receptor alpha antibody
  DISEASE   Asthma, eosinophilic phenotype [DS:H00079]
  TYPE      Monoclonal antibody
TARGET      IL5RA (CD125) [HSA:3568] [KO:K05067]
  PATHWAY   hsa04060(3568)  Cytokine-cytokine receptor interaction
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             R RESPIRATORY SYSTEM
              R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
               R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
                R03DX Other systemic drugs for obstructive airway diseases
                 R03DX10 Benralizumab
                  D09874  Benralizumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Respiratory Tract/Pulmonary Agents
              Respiratory Tract Agents, Other
               Immunomodulators
                Benralizumab
                 D09874  Benralizumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              22  Respiratory organ agents
               229  Miscellaneous
                2290  Miscellaneous
                 D09874  Benralizumab (USAN/INN); Benralizumab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Immunological agent
              DG02019  Interleukin inhibitor
               D09874  Benralizumab
            Drug classes [BR:br08332]
             Immunological agent
              DG02019  Interleukin inhibitor
               D09874  Benralizumab
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokine receptors
               Interleukin receptors
                IL5RA (CD125)
                 D09874  Benralizumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09874
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09874
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D09874
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09874
DBLINKS     CAS: 1044511-01-4
            PubChem: 124490602
///
